Nanchang, China-On November 8, 2021, Toumai^® Laparoscopic Surgical Robot (hereafter referred to as “Toumai^®”) independently developed by Shanghai MicroPort MedBot (Group) Co., Ltd. (hereafter referred to as "MicroPort^® MedBot^®") successfully held the kick-off meeting of clinical trial in the First Affiliated Hospital of Nanchang University. This multi-disciplinary and multi-center clinical trial is the first Chinese-developed four-arm surgery robot clinical trial carried out in Jiangxi Province. It is of great significance to promote the development of Chinese-developed surgery robot.

On November 11, 2021, Professor Li Taiyuan, director of General Surgery Department of the First Affiliated Hospital of Nanchang University, operated Toumai^® to complete a robot-assisted radical resection of sigmoid colon cancer. Compared with manual manipulation and traditional Laparoscopic minimally invasive surgery, the robot surpasses the limits of the human hand. The surgical instruments with high dexterity can realize more flexible and accurate surgical operation in narrow space and improve the precision of surgical operation. The surgery robot can also filter the tremor, restrain, or even eliminate the involuntary tremor at the end of the instrument, so as to ensure the operation precision. With multi-arm operation, the surgery robot can also realize the main surgeon's independent control of laparoscope and auxiliary pulling instruments, intuitively realize the operation intention of the surgeon and improve the operation efficiency.

At present, Toumai^® Laparoscopic Surgical Robot has officially launched multi-disciplinary and multi-center clinical trial across the country for clinical treatment in general surgery, thoracic surgery, gynecology and other departments, which indicates that Chinese-developed surgery robot has the ability to assist doctors to complete complex surgery in narrow anatomical space.

Liu Yu, Chief Commercial Officer of MicroPort^® Medbot^®, said: “Thanks to the support of the First Affiliated Hospital of Nanchang University for Chinese-developed surgical robot. Professor Li Taiyuan performed the robot-assisted radical operation of sigmoid colon cancer by using Toumai^®, which fully reflects the superb clinical technology and professional strength of Professor Li Taiyuan. We look forward to promoting the innovation and iteration of Chinese-developed robots through the further development of the multi-disciplinary clinical trial of Toumai^® in the First Affiliated Hospital of Nanchang University, so as to provide patients with less invasive, more accurate and inclusive medical services and realize the initial goal of “Make surgery easier, safer and less invasive”.